lecanemab
Selected indexed studies
- Lecanemab in Early Alzheimer's Disease. (N Engl J Med, 2023) [PMID:36449413]
- Lecanemab: Appropriate Use Recommendations. (J Prev Alzheimers Dis, 2023) [PMID:37357276]
- Updated safety results from phase 3 lecanemab study in early Alzheimer's disease. (Alzheimers Res Ther, 2024) [PMID:38730496]
_Worker-drafted node — pending editorial review._
Connections
lecanemab is a side effect of
Sources
- Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis. (2024) pubmed
- Lecanemab in Early Alzheimer's Disease. (2023) pubmed
- Lecanemab: Appropriate Use Recommendations. (2023) pubmed
- Updated safety results from phase 3 lecanemab study in early Alzheimer's disease. (2024) pubmed
- Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. (2023) pubmed
- Lecanemab. (2012) pubmed
- Lecanemab. (2024) pubmed
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. (2021) pubmed
- Lecanemab: Appropriate Use Recommendations by Korean Dementia Association. (2024) pubmed
- Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. (2022) pubmed